Matthew OSullivan
Overview
Explore the profile of Matthew OSullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asquith W, Hueston L, Dwyer D, Kok J, Ko D, Fennel M, et al.
J Med Virol
. 2024 Jan;
96(1):e29407.
PMID: 38240403
In response to the emergence of the monkeypox virus (MPXV) in Australia in May 2022, we developed and evaluated indirect immunofluorescence assays (IFA) for MPXV and Vaccinia virus (VACV) IgG...
2.
Legg A, Roberts M, Davies J, Cass A, Meagher N, Sud A, et al.
Open Forum Infect Dis
. 2023 Jul;
10(7):ofad337.
PMID: 37496601
Background: The Combination Antibiotic Therapy for Methicillin-Resistant (CAMERA2) trial ceased recruitment in July 2018, noting that a higher proportion of patients in the intervention arm (combination therapy) developed acute kidney...
3.
Fong W, Rockett R, Agius J, Chandra S, Johnson-Mckinnon J, Sim E, et al.
BMC Infect Dis
. 2023 May;
23(1):303.
PMID: 37158832
The emergence of resistance to antiviral drugs increasingly used to treat SARS-CoV-2 infections has been recognised as a significant threat to COVID-19 control. In addition, some SARS-CoV-2 variants of concern...
4.
Colaco C, OSullivan M, Zhang H, Huynh D, Sintchenko V, Oftadeh S, et al.
Intern Med J
. 2023 Mar;
53(11):2028-2034.
PMID: 36872866
Background: Streptococcus pneumoniae (pneumococcus) is a human nasopharyngeal tract coloniser responsible for invasive pneumococcal disease, which is largely vaccine preventable. Vaccination is recommended from birth for all, and through adulthood...
5.
Jackson J, Chan C, McBurnie J, La Hera-Fuentes G, Burston J, Bridges L, et al.
Aust N Z J Public Health
. 2023 Jan;
47(1):100003.
PMID: 36680916
Objective: To describe the effectiveness of the public health response to COVID-19 in our local region by documenting detection of SARS-CoV-2 infection by nucleic acid testing (NAT) positivity and seroprevalence....
6.
Hasan T, Lim H, Hueston L, Dwyer D, OSullivan M
Pathology
. 2021 Oct;
53(7):917-919.
PMID: 34635322
No abstract available.
7.
Avazzadeh S, Quinlan L, Reilly J, McDonagh K, Jalali A, Wang Y, et al.
BMC Neurosci
. 2021 Sep;
22(1):56.
PMID: 34525970
Background: NRXN1 deletions are identified as one of major rare risk factors for autism spectrum disorder (ASD) and other neurodevelopmental disorders. ASD has 30% co-morbidity with epilepsy, and the latter...
8.
Sintchenko V, Timms V, Sim E, Rockett R, Bachmann N, OSullivan M, et al.
Front Med (Lausanne)
. 2021 Apr;
8:641260.
PMID: 33928102
Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to "disarm" rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use,...
9.
Branley J, OSullivan M, Polkinghorne A, Poljak M, Stephens D
Pathology
. 2020 Aug;
52(7):821-823.
PMID: 32798071
No abstract available.
10.
Denholm J, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T, et al.
Trials
. 2020 Jul;
21(1):646.
PMID: 32665040
Objectives: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2...